Built around direct experience leading complex CMC programs.
Ghlobe Pharma's advisory model is informed by senior operating experience across late-stage small-molecule development, global manufacturing networks, clinical supply, and registration readiness. The emphasis is practical: identify the technical and execution risks that can change a program's trajectory, then build the operating system required to resolve them.
Executive CMC leadership
Leadership of integrated CMC and Technical Operations organizations supporting clinical-stage portfolios, pivotal development, and programs preparing for registration and launch.
Drug substance and global manufacturing
Process development, scale-up, technology transfer, registration strategy, external manufacturing oversight, and global supply-network design across complex small-molecule programs.
Drug product and enabling technologies
Formulation and drug-product development with direct experience in technically demanding intermediate and particle-engineering processes, including spray drying, scale-up, dissolution performance, and process troubleshooting.
Pivotal and registration-stage execution
CMC strategy spanning End-of-Phase 2 preparation, Phase 3 readiness, method validation, comparability, registration stability, registration manufacturing, and validation planning.
Clinical and commercial supply
Clinical supply strategy, packaging and labeling, IRT interfaces, global distribution, demand planning, launch readiness, and supply-continuity risk management.
CDMO governance and technical recovery
Selection and oversight of external development and manufacturing partners, technology-transfer leadership, escalation of critical technical issues, and recovery planning when scale-up or manufacturing performance diverges from expectations.
From technical workstreams to one integrated development system.
The differentiator is not simply familiarity with individual CMC disciplines. It is the ability to connect drug substance, intermediate, drug product, analytical, regulatory, clinical supply, and external manufacturing decisions to the same development critical path.
